- Home
- BMEA vs BYSI Comparison
BMEA vs BYSI Comparison
Compare BMEA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- BYSI
- Stock Information
- Founded
- BMEA 2017
- BYSI 2010
- Country
- BMEA United States
- BYSI United States
- Employees
- BMEA N/A
- BYSI N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- BYSI Health Care
- Exchange
- BMEA Nasdaq
- BYSI Nasdaq
- Market Cap
- BMEA 65.8M
- BYSI 72.1M
- IPO Year
- BMEA 2021
- BYSI 2017
- Fundamental
- Price
- BMEA $1.67
- BYSI $1.66
- Analyst Decision
- BMEA Strong Buy
- BYSI
- Analyst Count
- BMEA 11
- BYSI 0
- Target Price
- BMEA $27.60
- BYSI N/A
- AVG Volume (30 Days)
- BMEA 713.5K
- BYSI 32.8K
- Earning Date
- BMEA 05-05-2025
- BYSI 01-01-0001
- Dividend Yield
- BMEA N/A
- BYSI N/A
- EPS Growth
- BMEA N/A
- BYSI N/A
- EPS
- BMEA N/A
- BYSI N/A
- Revenue
- BMEA N/A
- BYSI N/A
- Revenue This Year
- BMEA N/A
- BYSI N/A
- Revenue Next Year
- BMEA N/A
- BYSI N/A
- P/E Ratio
- BMEA N/A
- BYSI N/A
- Revenue Growth
- BMEA N/A
- BYSI N/A
- 52 Week Low
- BMEA $1.53
- BYSI $0.98
- 52 Week High
- BMEA $13.43
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- BMEA 41.85
- BYSI 54.68
- Support Level
- BMEA $1.61
- BYSI $1.64
- Resistance Level
- BMEA $2.30
- BYSI $2.14
- Average True Range (ATR)
- BMEA 0.20
- BYSI 0.17
- MACD
- BMEA -0.00
- BYSI 0.03
- Stochastic Oscillator
- BMEA 21.74
- BYSI 50.60
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.